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Background: The payment structure for the New Medicine Service (NMS) in England is based on the assumption
that 0.5% of prescription items dispensed in community pharmacies are eligible for the service. This assumption is
based on a theoretical calculation. This study aimed to find out the actual proportion of prescription items eligible
for the NMS dispensed in community pharmacies in order to compare this with the theoretical assumption. The
study also aimed to investigate whether the proportion of prescription items eligible for the NMS is affected by
pharmacies’ proximity to GP practices.
Methods: The study collected data from eight pharmacies in Nottingham belonging to the same large chain of
pharmacies. Pharmacies were grouped by distance from the nearest GP practice and sampled to reflect the
distribution by distance of all pharmacies in Nottingham. Data on one thousand consecutive prescription items
were collected from each pharmacy and the number of NMS eligible items recorded. All NHS prescriptions were
included in the sample. Data were analysed and proportions calculated with 95% confidence intervals used to
compare the study results against the theoretical figure of 0.5% of prescription items being eligible for the NMS.
Results: A total of 8005 prescription items were collected (a minimum of 1000 items per pharmacy) of which 17
items were eligible to receive the service. The study found that 0.25% (95% confidence intervals: 0.14% to 0.36%) of
prescription items were eligible for the NMS which differs significantly from the theoretical assumption of 0.5%. The
opportunity rate for the service was lower, 0.21% (95% confidence intervals: 0.10% to 0.32%) of items, as some
items eligible for the NMS did not translate into opportunities to offer the service. Of all the prescription items
collected in the pharmacies, 28% were collected by patient representatives.
Conclusions: The results of this study show that the proportion of items eligible for the NMS dispensed in
community pharmacies is lower than the Department of Health assumption of 0.5%. This study did not find a
significant difference in the rate of NMS opportunities between pharmacies located close to GP practices compared
to those further away.
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In October 2011 the New Medicine Service (NMS)
was introduced into community pharmacies in England
to support patients prescribed new medicines for speci-
fied long term conditions (hypertension, type 2 dia-
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unless otherwise stated.and patients receiving anti-coagulant/antiplatelet agents).
The service aims to improve adherence to medicines and
reduce medicines wastage [1]. The service consists of
three parts, patient engagement (classified as usual care),
the intervention and the follow-up. The intervention and
follow-up stages consist of a semi-structured interview
between the patient and pharmacist, which can be held
in the pharmacy or by telephone, to support patients in
their medicine taking and to highlight any problems
they may be experiencing with their new medicine. Thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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sible or refer the patient to their prescriber if necessary [1].
A patient is eligible to receive the NMS if they are pre-
scribed a new medicine indicated for one of the eligible
conditions and appears on the list of eligible medicines in
the service specification [1]. The NMS can only be con-
ducted where the patient (or, in the case of children,
patient’s parent) can provide written consent.
Research conducted in the UK and Finland has found
that adequate remuneration is an important facilitator to
service provision and where payment is seen as inad-
equate, it can inhibit the uptake of services [2-5]. The
payment structure for the NMS has been identified as a
potential barrier to implementation [6].
The NMS service was initially funded in the first year
by creating a fund of up to £55 m for the first 12 months
of the service, which included payment for training and
implementation. This was based on the assumption that
0.5% of all prescription items dispensed in community
pharmacies would be eligible for the service [7]. This
figure was the result of analysis by the Department of
Health and is based on a theoretical figure due to data
available at that time. The service has now been op-
erating for over a year, making it timely to investigate
the actual opportunity rate for the NMS in community
pharmacies.
Community pharmacists and superintendent pharma-
cists (a strategic role, taking ultimate responsibility for
pharmacists employed by their organizations, and the
services they provide) [8] have questioned the assump-
tion, reporting that the proportion of eligible items seen
in their pharmacies is less than 0.5% of the items dis-
pensed and have given several potential reasons for this.
They suggested that the location of a pharmacy would
affect the numbers of eligible items dispensed, as pa-
tients prescribed a new medicine by their doctor are
more likely to get the prescription dispensed at the near-
est pharmacy, even where this is not the pharmacy they
regularly use. Additionally they proposed that this could
mean that pharmacies co-located with health centres
would see more eligible items than pharmacies located
further away from GP practices. They also suggested
that pharmacies that dispensed a higher proportion of
Misuse of Drugs Act (MDA) prescriptions (instalment
prescriptions used in the treatment of substance misuse)
would have a lower proportion of eligible items com-
pared to those who did not. In addition they reported
that some items which appear eligible may not translate
into a NMS opportunity, for example, if consent cannot
be gained because the item is dispensed as part of a care
home service (unpublished data; Wells K, Boyd MJ,
Thornley T, Boardman HF). The implication of this is
that pharmacies may not be able to access the full
amount of funding allocated to the NMS if the rate ofopportunities to provide the NMS is less that the theor-
etical rate of 0.5%. In April 2012 the Pharmaceutical
Services Negotiating Committee (PSNC) acknowledged
that the theoretical assumption may not reflect the rate of
NMS opportunities for all pharmacies and has stated that
it will be reconsidered in the future when data regarding
the actual rate of NMS opportunities are available [7].
This study’s primary aim was to investigate the actual
proportion of items dispensed in community pharmacies
that are eligible for the NMS in practice and to compare
this to the theoretical proportion of 0.5%. In addition
the proportion of items eligible for the NMS at pharma-
cies close to General Practitioner (GP) practices was
compared with those further away to determine whether
distance from a GP practice affects the proportion of
NMS eligible items presented in pharmacies.
Methods
This study was carried out in pharmacies in Nottingham
belonging to a large chain to minimise inter-pharmacy
variation. At least one thousand consecutive prescription
items were sampled from each pharmacy (a total of 8005
items) as for most pharmacies this represents several
days prescriptions and enables several pharmacies in dif-
ferent locations to be sampled to provide a broader
picture. This provided a balance between collecting large
numbers of prescription items and being more represen-
tative of an individual pharmacy, and collecting from a
wide range of pharmacy location types to be more repre-
sentative of the pharmacy sector. The sample size soft-
ware nQuery Advisor version 6 was used to conduct a
sample size calculation based on the primary outcome to
estimate a proportion with 95% confidence intervals to a
power of 90%. This showed that 7852 prescription items
were needed in total to detect a 0.5% difference (a 0.0025%
change in prescription items eligible for the NMS), allow-
ing for clustering effects, therefore data from at least 7852
prescription items would be collected.
The research team were advised by University Re-
search Governance and the local Primary Care Trust
Research and Development leads that ethical approval
was not required as this study was an audit - the re-
searcher conducting the study was a part time employee
of the pharmacy chain from which the data was collected
and there was no intervention. The study protocol was
reviewed by a senior academic at the University of
Nottingham and approval gained from the pharmacy chain
head office and relevant area managers.
The 17 pharmacies belonging to a large multiple in
Nottingham were grouped into three distances from GP
practices: less than 100 meters, 100-500 meters and over
500 meters and the three groups were sampled to reflect
as closely as possible the distribution of all pharmacies
in Nottingham. These distances were chosen in order to
Table 1 The types of prescription items included in the
data collection
Types of NHS prescription Number of items recorded (%)
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GP practices, and pharmacies further away from GP
practices. The distances were calculated by entering the
pharmacy postcode into the “Find GP Services” page
of the NHS choices website (www.nhs.uk). Pharmacies
were excluded from the study if they dispensed less than
1000 prescription items per week (so that data collected
in each pharmacy would be sufficient), if the pharmacy’s
staffing levels required more than one person to receive
and hand out prescriptions, meaning that more than one
researcher would be needed to collect the data, or if the
pharmacy primarily catered to an atypical demographic
and are therefore unrepresentative meaning that the re-
sults from the pharmacy would be unlikely to reflect the
average demographics seen by pharmacies. One phar-
macy was excluded from the study because they dis-
pensed less than 1000 items per week. Two pharmacies
were excluded from the study because they required
more than one person to receive and hand out prescrip-
tions. One pharmacy was excluded due to its atypical
demographic. This pharmacy was located within a uni-
versity health centre and mainly caters to young people
who are unlikely to require medicines for hypertension,
COPD, type 2 diabetes or need anti-platelet agents or
anticoagulants as these are conditions mainly affecting
older people. Therefore this pharmacy could be expected
to have a lower opportunity rate for the NMS than other
pharmacies. Eight pharmacies were sampled from the
remaining 12 possible pharmacies reflect the distribution
of pharmacies in Nottingham according to distance from
GP surgery. After gaining approval from the head office
of the large chain and area managers, pharmacies were
contacted directly by a researcher to be invited to par-
ticipate in the study.
In each pharmacy the data were collected by a re-
searcher taking in and handing out prescriptions to
patients. Prescriptions were included in the study if they
were a National Health Service (NHS) prescription, re-
gardless of who collected the prescription, what type of
NHS prescription it was, or whether the prescription was
dispensed as part of a care home service. Prescriptions
were only excluded from the study if they were private
non-NHS prescriptions. A prescription item was eligible
to receive the NMS if it was newly prescribed for hyper-
tension, type 2 diabetes, asthma/COPD or was an anti-
platelet or anti-coagulant agent, and the medicine was
included in the list of medicines eligible for the NMS as
specified in the service specification [1]. A prescription
item meeting these criteria for the NMS was recorded in
the study as eligible to receive the service regardless of
who collected the prescription or whether it was part of a
care home service. Therefore the study recorded the num-
ber of prescription items dispensed that were eligible to
receive the NMS as well as actual NMS opportunities.For each NHS prescription the researcher recorded
the number of items on the prescription, whether the
patient or a representative collected the prescription, if
the prescription was delivered, whether the prescription
was a MDA form or part of a care home service. Where
an item was eligible for the NMS, the therapeutic class it
fell into was recorded along with whether or not the
NMS was offered and whether it was declined (and a
brief reason why if provided by the patient). This study
also recorded instances where items which were eligible
for the NMS did not translate into an opportunity for
the pharmacy to provide the service, for example where
the patient was a child unable to consent to the service,
or the patient was a care home resident. Data relating to
private prescriptions were not recorded as only NHS
prescriptions are eligible for the NMS. The data were
collected between January and May 2013.
The data collected were inputted into the statistical
software SPSS and frequency counts with percentages
determined. Proportions were calculated with 95% confi-
dence intervals and the confidence intervals used to
compare the study results against the estimate that 0.5%
of prescription items are eligible for the NMS [9].
Results
In total 8005 items were recorded in 8 pharmacies in
Nottingham (a minimum of 1000 items in each pharmacy)
and of these 6080 items (76%) were NHS prescription
items that were not MDA items or for care home residents
(Table 1). Of the 8005 items recorded, 1965 (25%) were
delivered to the patient or care home, and the remaining
6040 (75%) were collected from the pharmacies. Of
the prescription items collected in the pharmacies, 28%
(n = 1720) were collected by patient representatives.
In this study 20 prescription items, 0.25% (95% CIs
0.14%-0.36%), were eligible for the NMS. This differs
significantly from the assumption that 0.5% of prescrip-
tion items are eligible for the NMS (z = 14.33). There
were 17 opportunities (0.21%, 95% CIs 0.10%-0.32%) to
provide the NMS (Table 2) as not all the eligible items
translated into opportunities to offer the NMS. Three
items were prescribed for the treatment of asthma in
children who could not consent to the service (Table 3).
The NMS was offered to 16 of the 17 patients that
Table 2 The percentage of NMS opportunities and NMS eligible items by distance from nearest GP practice
Distance of pharmacy
from nearest GP practice
Number of
items collected
Eligible items NMS opportunities
Number Percentage with 95% CIs Number Percentage with 95% CIs
<100 m n = 2002 7 0.35 (0.09-0.61) 6 0.30 (0.06-0.54)
100-500 m n = 5004 11 0.22 (0.09-0.35) 9 0.18 (0.05-0.31)
>500 m n = 999 2 0.20 - 2 0.20 -
Total n = 8005 20 0.25 (0.14-0.36) 17 0.23 (0.10-0.32)
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one opportunity where the service was not offered was
where a patient’s representative collected the dispensed
prescription. The service was declined by 2 of the 16
patients offered the NMS, both of whom had been pre-
scribed an anti-coagulant. Both patients stated the
reason for declining the service was that they were re-
ceiving a lot of support from other healthcare profes-
sionals and felt that the support offered by the NMS was
not needed.
There was no significant difference between the
proportion of NMS eligible items at pharmacies close
to GP practices compared with those further away
(difference = 0.13%, 95% CIs -0.14% to 0.42%).
Discussion
This study found that 0.25% of prescription items dis-
pensed in community pharmacies are eligible for the
NMS which is significantly different from the Depart-
ment of Health’s theoretical assumption that 0.5% of
prescription items would be eligible. It is possible that in
calculating the 0.5% estimate the effect of some factors
affecting the number of eligible items, such as prescrip-
tions for care home residents, were underestimated, pos-
sibly explaining the difference between the observed
number of eligible prescription items and the theoretical
estimate.
Pharmacists were able to earn up to £55 m in the first
year of the service based on pharmacists performing the
NMS for 0.5% of their prescription items each month. In
order to be remunerated for the NMS conducted, phar-
macies claim payment each month for completed NMS
in the same way that payment is claimed for NHS pre-
scriptions dispensed. The results from this study would
suggest that pharmacists were not able to access the fullTable 3 The number of NMS eligible items and
opportunities to provide the service by disease state









9 5 1 5
Number of NMS
opportunities
6 5 1 5potential funding as the number of opportunities to
carry out the NMS is less than 0.5% of their prescription
items. NMS funding is outside the total agreed funding
for pharmacy contractors, and if it is not earned then
contractors are no longer able to access it and is not
guaranteed to be made available for other public health
initiatives. In April 2012 the PSNC communicated that
theoretical assumption may not reflect the rate of NMS
opportunities for all pharmacies and has stated that it
will be reconsidered in the future [7]. This study sug-
gests that the actual rate of NMS opportunities is less
that the theoretical rate which means that it would be
possible to widen the scope of the NMS by including
other conditions eligible for the service to increase the
number of opportunities a pharmacist has to conduct
the NMS and consequently the number of patient who
could benefit, without exceeding the funding limit.
Studies examining the provision of other UK phar-
macy services have found that adequate funding is
important to the success of a service [2-4]. This is not
unique to the UK; research conducted in Finland has
also found that pharmacies must be adequately reim-
bursed for providing a service if the service is going to
be successful long term [5]. This study suggests that the
assumptions used to calculate the funding envelope for
the NMS are flawed as the actually opportunity rate to
provide the service is less than the theoretical rate that
underpins the potential funding available. This highlights
the importance of evidence based methodologies to cal-
culate funding allocation and applies not only to service
in the UK but pharmacy services worldwide.
The results of this study suggest that a pharmacy’s op-
portunity rate to provide the NMS is less than the num-
ber of eligible items dispensed. In this study the reason
for this was that eligible items were prescribed to patients
who were not able to take part in the service because their
age prevented them from being able to consent. The ser-
vice to patients with asthma and is likely to be affected by
this more than the other groups as children are less likely
to have hypertension, type II diabetes or require anti-
platelet agents or anti-coagulants, than asthma [10-16].
Of the 17 opportunities to offer the NMS in this study,
there was just one occasion where the NMS was not
offered to the patient, suggesting that the pharmacists en-
gaged with the service take most available opportunities to
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mentation of Medicine Use Reviews (MURs), where a na-
tional evaluation found that pharmacies offering MURs
provided just 13.7% of the maximum number of MURs
that could have been claimed for, despite this service being
available for patients with any long term therapy [13]. A
study carried out before the implementation of the NMS
suggested that pharmacist engagement and NMS uptake
would be greater than it was for MURs because when
MURs were introduced it was seen as a change in direction
for pharmacy requiring a cultural shift, whereas the NMS
was seen as a natural extension of the role of community
pharmacists [6].
In this study there were 16 occasions when the NMS
was offered to patients and 2 occasions where the pa-
tient declined the service. The stated reason for this was
the same in both instances, that the patient felt that they
were receiving enough support from other healthcare
professionals. There is evidence to suggest that the rea-
son given by patients in a pharmacy for declining a ser-
vice may not be the sole or entire reason the patient did
not want the service [14], however both patients had
been prescribed anti-coagulant agents and were attend-
ing anti-coagulant clinics so it is possible that the de-
clines in this study indicate that some patients taking
anti-coagulants are content with the existing support
provided by other healthcare professionals.
In this study the most common condition receiving
the NMS was asthma/COPD, followed by hypertension
and anti-platelet agents/anti-coagulants with type II dia-
betes being the least common condition. National data
published by the Pharmaceutical Services Negotiating
Committee (PSNC) show that the most common NMS
condition receiving the service is hypertension (54.4%),
followed by asthma and COPD (26.4%), then type II dia-
betes (11.3%) with anti-platelet agent/anti-coagulant be-
ing the least common new medicines receiving the NMS
(7.9%) [15]. The likely reason for the difference between
the study data and the national data is likely to be due
to the small numbers of NMS recorded in this study. If
the sample size had been greater it is likely that the pro-
portions of conditions would reflect the national data.
Another possible reason for the difference between the
study data and national data is that all the pharma-
cies sampled were in the same geographical location
(Nottingham) and the demographics could potentially
be different to demographics nationally.
In this study 28% of prescription items were collected
by patient representatives, or proxies. While the pro-
portion of prescriptions collected by patient represen-
tatives nationally is unknown, it is widely reported
that around a third of requests for health information
and non-prescription medicines in pharmacies are made
by proxies [16-18].The results of this study did not find a statistical
difference between the proportions of NMS eligible
prescription items dispensed in pharmacies co-located
with GP practices and pharmacies further away. How-
ever, the study was not powered to test this so it is
possible that with a larger sample size a difference may
be detected.
Limitations
One limitation of this study is that just 8 pharmacies
in Nottingham were sampled (out of a total of 97) so
it is possible that the study pharmacies would not re-
flect pharmacies locally. Therefore this study endea-
voured to reflect the distribution of all pharmacies in
Nottingham when sampling pharmacies. It was not
possible to exactly match the distribution of pharmacies in
Nottingham however, as there were just 2 pharmacies
available in the <100 m group that matched the inclusion
criteria.
Another limitation of the study is that all the pharma-
cies sampled were located in Nottingham and belonged
to the same large chain, so it is possible that the phar-
macies did not represent community pharmacy nation-
ally. In addition the study collected 1000 items per
pharmacy over a maximum of 6 days so there is a possi-
bility that the 1000 items collected from each pharmacy
did not represent a typical week’s prescription items for
that pharmacy. However the pharmacies were selected
to include a range of types and locations across the
Nottingham area and data collection was spread over
five months in an attempt to minimise these effects.
In this study pharmacies were excluded if they dis-
pensed less than 1000 items per week or if the phar-
macy’s staffing levels required more than one member of
staff to take in and hand out prescriptions as this could
have introduced potential selection bias. These demo-
graphic exclusions may reduce full generalizability and is
a limitation of the study.
The pharmacies in this study were sampled over
5 months which could be a limitation as number and
type of prescription items can vary over time, meaning
that the data collected from an individual pharmacy may
not reflect its long term dispensing patterns. However,
by sampling pharmacies over 5 months the effect of sea-
sonal prescribing patterns on the whole sample was
reduced.
Conclusions
The results of this study show that the proportion of
items eligible for the NMS dispensed in community
pharmacies is lower than the Department of Health
assumption of 0.5%. Therefore pharmacy was not go-
ing to reach the maximum potential income of up to
£55million in the first year, making it possible to widen
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benefit more patients without exceeding the available
funding. This study did not find a significant difference
in the rate of NMS opportunities between pharmacies
located close to GP practices compared to those further
away.
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